Caris Life Sciences
CAI
27.10
-0.36
-1.29%
Caris Life Sciences
US · CAI
#1669 by market cap
Listed 2025
27.10
-0.36
-1.29%
Live - 5344 symbols - heartbeat 401s ago
· 2026-10-08 08:29
Pre-market
26.51
-2.18%
After-hours
27.10
0.00%
Overnight
26.88
-0.81%
- Market cap
- 7.66B
- P/E (TTM)i
- 72.85
- P/Bi
- 12.94
- EPSi
- -1.90
- Div yieldi
- 0.00%
- 52W posi
- 66%
Reader sentiment
Are you bullish or bearish on CAI?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 6.99, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 4 years
Latest year +96.97% YoY
Margins
- Gross margin
- 66.40%
- Operating margin
- 5.56%
- Net margin
- -66.25%
Key ratios & quality
- Enterprise valuei
- 7.24B
- Altman Z-Scorei
- 6.99
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 258.49M | 306.13M | 412.26M | 812.03M |
| Gross profit | 80.02M | 89.31M | 178.78M | 539.17M |
| Selling & admin expenses | 294.51M | 291.98M | 321.99M | 392.47M |
| Research & development | 101.27M | 116.88M | 113.92M | 101.58M |
| Operating profit | -315.76M | -319.55M | -257.12M | 45.11M |
| Pretax profit | -320.83M | -341.42M | -281.89M | -68.09M |
| Tax | 0 | 0 | 0 | 0 |
| Net profit | -320.83M | -341.42M | -281.89M | -68.09M |
| Basic EPS | -2 | -2 | -1 | -3 |
| Diluted EPS | -1.57 | -1.82 | -1.36 | -3.22 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 120.92M | 181.40M | 216.83M | 292.89M | 216.17M | 263.71M |
| Gross profit | 57.06M | 113.69M | 147.51M | 220.91M | 141.35M | 179.60M |
| Selling & admin expenses | 91.95M | 106.63M | 93.24M | 100.66M | 104.75M | 120.31M |
| Research & development | 23.07M | 25.05M | 21.62M | 31.85M | 31.32M | 32.36M |
| Operating profit | -57.95M | -17.99M | 32.64M | 88.41M | 5.28M | 26.93M |
| Pretax profit | -102.58M | -71.79M | 24.33M | 81.96M | -644.00K | -614.00K |
| Tax | 0 | 0 | 0 | 0 | -134.00K | 23.00K |
| Net profit | -102.58M | -71.79M | 24.33M | 81.96M | -510.00K | -637.00K |
| Basic EPS | 0 | -8 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.46 | -7.97 | 0.08 | 0.28 | 0.00 | 0.00 |
Balance sheet
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total current assets | 516.04M | 242.61M | 215.73M | 997.80M |
| Cash & ST investments | 409.62M | 121.59M | 66.15M | 798.57M |
| Inventory | 46.96M | 49.00M | 39.57M | 63.63M |
| Total assets | 717.42M | 412.90M | 343.73M | 1.13B |
| Total current liabilities | 136.91M | 95.14M | 165.42M | 127.15M |
| Short-term debt | 57.09M | 6.59M | 66.17M | 6.53M |
| Long-term debt | 169.57M | 166.11M | 319.20M | 378.45M |
| Total liabilities | 2,419,535,000.00 | 2,557,850,000.00 | 2,842,572,000.00 | 548,356,000.00 |
| Total equity | -1.70B | -2.14B | -2.50B | 577.31M |
| Retained earnings | -1.68B | -2.12B | -2.47B | -2.55B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 171.23M | 833.32M | 854.25M | 997.80M | 1.01B | 1.06B |
| Cash & ST investments | 33.43M | 721.18M | 755.49M | 798.57M | 823.46M | 793.12M |
| Inventory | 36.55M | 40.61M | 49.30M | 63.63M | 76.29M | 123.79M |
| Total assets | 291.58M | 955.06M | 984.57M | 1.13B | 1.16B | 1.23B |
| Total current liabilities | 162.55M | 90.18M | 86.03M | 127.15M | 143.90M | 191.44M |
| Short-term debt | 66.12M | 7.39M | 6.61M | 6.53M | 6.01M | 6.55M |
| Long-term debt | 316.64M | 373.61M | 376.30M | 378.45M | 381.40M | 392.97M |
| Total liabilities | 2,891,448,000.00 | 502,154,000.00 | 506,207,000.00 | 548,356,000.00 | 568,898,000.00 | 637,886,000.00 |
| Total equity | -2.60B | 452.90M | 478.36M | 577.31M | 593.49M | 591.73M |
| Retained earnings | -2.58B | -2.66B | -2.63B | -2.55B | -2.55B | -2.55B |
Cash flow
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Operating cash flow | -285.71M | -276.10M | -245.20M | 83.16M |
| Depreciation & amortization | 48.25M | 49.00M | 48.91M | 22.62M |
| Free cash flow | -327.96M | -298.42M | -253.64M | 66.90M |
| Dividends paid | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 0 | 0 | 528.35M |
| Ending cash balance | 111.14M | 60.01M | 68.03M | 800.04M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -31.34M | 7.29M | 62.43M | 44.78M | 32.88M | 28.48M |
| Depreciation & amortization | 7.05M | 6.41M | 4.87M | 4.29M | 5.07M | 6.54M |
| Free cash flow | -34.03M | 5.90M | 55.33M | 39.69M | 22.53M | 6.40M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -22.00K | 528.46M | 0 | -91.00K | 0 | -21.36M |
| Ending cash balance | 35.29M | 722.69M | 756.98M | 800.04M | 823.39M | 692.75M |
Returns & efficiency
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| ROE %i | -- | -- | -- | -- |
| ROA %i | -55.73 | -81.84 | -181.96 | -73.22 |
| ROIC %i | -- | -- | -- | -- |
| 5-year avg ROE %i | -- | -- | -- | -- |
| EBIT margin %i | -113.80 | -101.20 | -56.24 | -1.38 |
| FCF / sales %i | -- | -- | -- | 8.24 |
| Current ratioi | 3.77 | 2.55 | 1.30 | 7.85 |
| Quick ratioi | 3.29 | 1.86 | 0.93 | 7.16 |
| Debt / assetsi | 37.76 | 52.58 | 123.43 | 37.99 |
| LT debt / equityi | -- | -- | -- | 72.95 |
| Interest coveragei | -11.03 | -9.80 | -4.63 | -0.20 |
| Revenue CAGR (3Y) %i | -- | -- | -- | 46.46 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -244.80 | -207.37 | -- | -- | 20.13 |
| ROA %i | -225.26 | -116.09 | -100.75 | -73.22 | -56.59 | 9.62 |
| ROIC %i | -- | -120.94 | -104.26 | -- | -- | 12.16 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -48.60 | -41.21 | -19.76 | -1.38 | 10.00 | 15.35 |
| FCF / sales %i | -- | -- | -- | 8.24 | 13.61 | 12.53 |
| Current ratioi | 1.05 | 9.24 | 9.93 | 7.85 | 7.05 | 5.53 |
| Quick ratioi | 0.70 | 8.56 | 9.09 | 7.16 | 6.35 | 4.75 |
| Debt / assetsi | 143.98 | 43.87 | 43.34 | 37.99 | 37.08 | 36.79 |
| LT debt / equityi | -- | 90.88 | 87.83 | 72.95 | 71.60 | 75.35 |
| Interest coveragei | -4.11 | -3.73 | -2.18 | -0.20 | 1.60 | 3.24 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Molecular profiling services is the largest reported line at 95.66% of revenue, across 2 reported segments.
- The next-largest line, Pharma research and development services, is a distant second at 4.34% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Molecular profiling services95.66%
Pharma research and development services4.34%
Quote time 2026-10-08 08:29:27 · For reference only, not investment advice and not tailored to your situation.